Home » Stocks » Kintara Therapeutics

Kintara Therapeutics, Inc. (KTRA)

Stock Price: $1.51 USD 0.01 (0.67%)
Updated Oct 23, 2020 12:39 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 35.55M
Revenue (ttm) n/a
Net Income (ttm) -9.13M
Shares Out 23.54M
EPS (ttm) -0.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $1.51
Previous Close $1.50
Change ($) 0.01
Change (%) 0.67%
Day's Open 1.46
Day's Range 1.43 - 1.55
Day's Volume 284,958
52-Week Range 0.38 - 1.95

More Stats

Market Cap 35.55M
Enterprise Value 33.16M
Earnings Date (est) Nov 16, 2020
Ex-Dividend Date n/a
Shares Outstanding 23.54M
Float 19.38M
EPS (basic) -0.87
EPS (diluted) -0.87
FCF / Share -0.76
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 271,216
Short Ratio 0.48
Short % of Float 1.40%
Beta 2.08
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 11.02
Revenue n/a
Operating Income -9.20M
Net Income -9.13M
Free Cash Flow -7.93M
Net Cash 2.39M
Net Cash / Share 0.10
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -145.95%
ROE -818.20%
ROIC 688.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$4.25*
(181.46% upside)
Low
3.00
Current: $1.51
High
6.00
Target: 4.25
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2020201920182017201620152014201320122011
Revenue----------
Operating Income-9.20-8.40-11.17-8.32-6.21-4.725.25-6.29-2.71-1.29
Net Income-9.13-8.05-11.14-8.08-8.86-4.35-6.36-8.29-2.40-1.33
Shares Outstanding10.442.572.091.201.090.950.800.740.330.21
Earnings Per Share-0.87-3.16-5.42-7.40-8.30-4.60--11.20-7.20-6.40
Operating Cash Flow-7.93-6.33-9.85-8.02-5.15-3.85-4.00-5.52-0.58-0.23
Capital Expenditures---0.01-0.02-0.02-----
Free Cash Flow-7.93-6.33-9.86-8.04-5.16-3.85-4.00-5.52-0.58-0.23
Cash & Equivalents2.393.725.976.596.161.754.764.140.020.00
Total Debt------0.280.270.26-
Net Cash / Debt2.393.725.976.596.161.754.483.86-0.250.00
Assets2.944.047.077.916.362.585.004.320.18-
Liabilities2.672.071.641.331.503.405.915.141.51-
Book Value0.261.975.446.584.86-0.82-0.90-0.82-1.33-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Kintara Therapeutics, Inc.
Country United States
Employees 4
CEO Saiid Zarrabian

Stock Information

Ticker Symbol KTRA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: KTRA

Description

Kintara Therapeutics, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was founded in 2009 and is headquartered in San Diego, California.